Penn Updates on CML: Do Cancer-Related Mutational Events at Diagnosis Predict Inferior Outcomes? Is Ponatinib Effective & Safe? Is Asciminib More Beneficial vs. Bosutinib in CP-CML Treated With > TKIs?
Login to view comments.
Click here to Login
